11 · Pattern recognition
Pattern recognition
Bookmarks need a Mind Club sign-in. How sign-in works
Pattern recognition across your briefsPan-RAS drugs move toward first line. Revolution’s chemotherapy combination and Erasca’s monotherapy both report pancreatic cancer responses this week, and both companies point to first-line Phase 3 trials. Neither result is randomized. Analysis
Tuberculosis regimens. NEJM’s PARADIGM4TB and BioVersys’s ENABLE both test new drug combinations against standard treatment; only the NEJM trial gives numbers. Analysis
Complement in myasthenia gravis. Livsayis follows Klygefa, which FDA lists as approved for the disease on 11.13; two approvals in a week give patients more dosing choices, not a new mechanism. Analysis